{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:35:30Z","timestamp":1790692530615,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40265-020-01298-9","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T12:02:35Z","timestamp":1585828955000},"page":"711-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps"],"prefix":"10.1007","volume":"80","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,2]]},"reference":[{"issue":"10209","key":"1298_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/S0140-6736(19)32133-6","volume":"394","author":"WW Stevens","year":"2019","unstructured":"Stevens WW. A new treatment for chronic rhinosinusitis with nasal polyps. Lancet. 2019;394(10209):1595\u20137.","journal-title":"Lancet"},{"issue":"100050","key":"1298_CR2","first-page":"1","volume":"12","author":"L Ren","year":"2019","unstructured":"Ren L, Zhang N, Zhang L, et al. Biologics for the treatment of chronic rhinosinusitis with nasal polyps: state of the art. World Allergy Organ J. 2019;12(100050):1\u20136.","journal-title":"World Allergy Organ J."},{"key":"1298_CR3","unstructured":"American Academy of Allergy Asthma and Immunology. Nasal polyps. 2019. https:\/\/www.aaaai.org\/conditions-and-treatments\/library\/allergy-library\/nasal-polyps. Accessed 13 Mar 2020."},{"issue":"1","key":"1298_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMcp1800215","volume":"381","author":"C Hopkins","year":"2019","unstructured":"Hopkins C. Chronic rhinosinusitis with nasal polyps. N Engl J Med. 2019;381(1):55\u201363.","journal-title":"N Engl J Med"},{"key":"1298_CR5","unstructured":"Sanofi-aventis US LLC and Regeneron Pharmaceuticals Inc. Dupixent\u00ae (dupilumab) injection, for subcutaneous use: US prescribing information. 2019. http:\/\/www.fda.gov\/. Accessed 13 Mar 2020."},{"key":"1298_CR6","unstructured":"Sanofi-aventis groupe. Dupixent (dupilumab) solution for injection: EU summary of product characteristics. 2020. http:\/\/www.ema.europa.eu\/. Accessed 13 Mar 2020."},{"key":"1298_CR7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s40265-019-01221-x","volume":"79","author":"E Deeks","year":"2019","unstructured":"Deeks E. Dupilumab: a review in moderate to severe asthma. Drugs. 2019;79:1885\u201395.","journal-title":"Drugs."},{"issue":"4","key":"1298_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40257-018-0370-9","volume":"19","author":"JE Frampton","year":"2018","unstructured":"Frampton JE, Blair HA. Dupilumab: a review in moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2018;19(4):617\u201324.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1298_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016;315(5):469\u201379.","journal-title":"JAMA"},{"issue":"10209","key":"1298_CR10","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350.","journal-title":"Lancet"},{"key":"1298_CR11","unstructured":"European Medicines Agency. Dupilumab: extension of indication variation assessment report. 2019. http:\/\/www.ema.europa.eu\/. Accessed 13 Mar 2020."},{"issue":"4","key":"1298_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/all.13685","volume":"74","author":"K Jonstam","year":"2019","unstructured":"Jonstam K, Swanson BN, Mannent LP, et al. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74(4):743\u201352.","journal-title":"Allergy"},{"key":"1298_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08734-z","author":"A Agarwal","year":"2019","unstructured":"Agarwal A, Spath D, Sherris DA, et al. Therapeutic antibodies for nasal polyposis treatment: where are we headed? Clin Rev Allergy Immunol. 2019. https:\/\/doi.org\/10.1007\/s12016-019-08734-z.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"1298_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhino50E2","volume":"50","author":"WJ Fokkens","year":"2012","unstructured":"Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1\u201312.","journal-title":"Rhinology."},{"issue":"Suppl 1","key":"1298_CR15","first-page":"S3","volume":"6","author":"RR Orlandi","year":"2016","unstructured":"Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis executive summary. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S3\u201321.","journal-title":"Int Forum Allergy Rhinol."},{"issue":"12","key":"1298_CR16","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312\u20139.","journal-title":"Allergy"},{"issue":"4","key":"1298_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","volume":"19","author":"G Agnihotri","year":"2019","unstructured":"Agnihotri G, Shi K, Lio PA. A clinician\u2019s guide to the recognition and management of dupilumab-associated conjunctivitis. Drugs R D. 2019;19(4):311\u20138.","journal-title":"Drugs R D."},{"issue":"3","key":"1298_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.anai.2019.07.004","volume":"123","author":"CD Codispoti","year":"2019","unstructured":"Codispoti CD, Mahdavinia M. A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol. 2019;123(3):232\u20139.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-020-01298-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T23:09:11Z","timestamp":1617318551000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-020-01298-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,2]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01298-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,2]]},"assertion":[{"value":"2 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sheridan Hoy is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}